Inogen’s (INGN) “Hold” Rating Reiterated at Needham & Company LLC

Needham & Company LLC reissued their hold rating on shares of Inogen (NASDAQ:INGN) in a report published on Wednesday morning,Benzinga reports.

Separately, StockNews.com raised shares of Inogen from a “hold” rating to a “buy” rating in a report on Monday, February 10th.

Inogen Stock Up 4.8 %

Inogen stock opened at $8.33 on Wednesday. Inogen has a twelve month low of $6.14 and a twelve month high of $13.33. The company has a 50 day moving average of $10.18 and a 200-day moving average of $10.23. The stock has a market capitalization of $198.40 million, a PE ratio of -3.70 and a beta of 1.02.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Royce & Associates LP boosted its holdings in Inogen by 167.4% in the third quarter. Royce & Associates LP now owns 51,891 shares of the medical technology company’s stock valued at $503,000 after acquiring an additional 32,482 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. grew its stake in shares of Inogen by 312.5% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 174,625 shares of the medical technology company’s stock valued at $1,694,000 after purchasing an additional 132,287 shares during the period. BNP Paribas Financial Markets grew its stake in shares of Inogen by 13.9% during the 3rd quarter. BNP Paribas Financial Markets now owns 42,137 shares of the medical technology company’s stock valued at $409,000 after acquiring an additional 5,131 shares during the period. Verition Fund Management LLC bought a new position in shares of Inogen during the 3rd quarter valued at approximately $106,000. Finally, Paloma Partners Management Co bought a new position in shares of Inogen during the 3rd quarter valued at approximately $126,000. Institutional investors own 89.94% of the company’s stock.

About Inogen

Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.